Johnson & Johnson's Orthopedic Biz Head: We are Still Struggling With the Integration of Synthes, Inc. a Year Later

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The world's largest healthcare group Johnson & Johnson (J & J) is struggling with the integration of almost a year ago for $ 19.7 billion acquired Swiss-American orthopedic specialist Synthes. "We still have less than half of the necessary work done," says Michel Orsinger, head of the newly created business unit DePuy Synthes, frankly. In an interview with "Finanz und Wirtschaft" he also acknowledges that DePuy Synthes lost in spinal implants business customers as well as employees in research and development. But Orsinger, who previously led the business as Chief Executive Officer of Synthes wants to look forward. He is convinced that Synthes is due to the merging better positioned with the orthopedic activities of J & J to cope with the increasing cost of healthcare.

Help employers find you! Check out all the jobs and post your resume.

Back to news